Benefits and risks during HRT: main safety issue breast cancer.

about

Benefits and risks during HRT: main safety issue breast cancer.

Item

http://www.wikidata.org/entity/Q38471535

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Benefits and risks during HRT: main safety issue breast cancer.

@en

type

Item

label

Benefits and risks during HRT: main safety issue breast cancer.

@en

prefLabel

Benefits and risks during HRT: main safety issue breast cancer.

@en

P1476

Benefits and risks during HRT: main safety issue breast cancer.

@en

P2093

Alfred O Mueck

http://www.w3.org/2001/XMLSchema#string

Xiangyan Ruan

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data.

P304

105-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1515/HMBCI.2011.014

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25961246

http://www.w3.org/2001/XMLSchema#string

Benefits and risks during HRT: main safety issue breast cancer.

about

Benefits and risks during HRT: main safety issue breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698